These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Reversible Airflow Obstruction Predicts Future Chronic Obstructive Pulmonary Disease Development in the SPIROMICS Cohort: An Observational Cohort Study. Buhr RG; Barjaktarevic IZ; Quibrera PM; Bateman LA; Bleecker ER; Couper DJ; Curtis JL; Dolezal BA; Han MK; Hansel NN; Krishnan JA; Martinez FJ; McKleroy W; Paine R; Rennard SI; Tashkin DP; Woodruff PG; Kanner RE; Cooper CB; Am J Respir Crit Care Med; 2022 Sep; 206(5):554-562. PubMed ID: 35549640 [No Abstract] [Full Text] [Related]
24. Clinical Significance of Symptoms in Smokers with Preserved Pulmonary Function. Woodruff PG; Barr RG; Bleecker E; Christenson SA; Couper D; Curtis JL; Gouskova NA; Hansel NN; Hoffman EA; Kanner RE; Kleerup E; Lazarus SC; Martinez FJ; Paine R; Rennard S; Tashkin DP; Han MK; N Engl J Med; 2016 May; 374(19):1811-21. PubMed ID: 27168432 [TBL] [Abstract][Full Text] [Related]
25. Low FVC/TLC in Preserved Ratio Impaired Spirometry (PRISm) is associated with features of and progression to obstructive lung disease. Fortis S; Comellas A; Kim V; Casaburi R; Hokanson JE; Crapo JD; Silverman EK; Wan ES Sci Rep; 2020 Mar; 10(1):5169. PubMed ID: 32198360 [TBL] [Abstract][Full Text] [Related]
26. Use of forced inspiratory vital capacity to identify bronchodilator reversibility in obstructive lung disease. Biring MS; Madison S; Mohsenifar Z J Asthma; 2001 Sep; 38(6):495-500. PubMed ID: 11642416 [TBL] [Abstract][Full Text] [Related]
27. Clinical Implications of Bronchodilator Testing: Diagnosing and Differentiating COPD and Asthma-COPD Overlap. Annangi S; Coz-Yataco AO Respir Care; 2022 Apr; 67(4):440-447. PubMed ID: 35338095 [TBL] [Abstract][Full Text] [Related]
28. Prevalence, Diagnostic Utility and Associated Characteristics of Bronchodilator Responsiveness. Beasley R; Hughes R; Agusti A; Calverley P; Chipps B; Del Olmo R; Papi A; Price D; Reddel H; Müllerová H; Rapsomaniki E Am J Respir Crit Care Med; 2024 Feb; 209(4):390-401. PubMed ID: 38029294 [No Abstract] [Full Text] [Related]
29. The prevalence of bronchodilator responsiveness of the small airway (using mid-maximal expiratory flow) in COPD - a retrospective study. Alobaidi NY; Almeshari MA; Stockley JA; Stockley RA; Sapey E BMC Pulm Med; 2022 Dec; 22(1):493. PubMed ID: 36585669 [TBL] [Abstract][Full Text] [Related]
30. Substantial variation exists in spirometry interpretation practices for airflow obstruction in accredited lung function laboratories across Australia and New Zealand. Holt NR; Thompson BR; Miller B; Borg BM Intern Med J; 2019 Jan; 49(1):41-47. PubMed ID: 30043534 [TBL] [Abstract][Full Text] [Related]
31. Parameter D: New Measure of Airflow Obstruction. Bhatt SP; Nakhmani A; Thimmegowda NM; Sthanam V; Wilson CG; Bhakta NR; Kim YI; Bodduluri S Ann Am Thorac Soc; 2023 Jul; 20(7):993-1002. PubMed ID: 36989246 [No Abstract] [Full Text] [Related]
32. The 'clinically significant' bronchodilator responsiveness (BDR) in children: a comparative study between six definitions of scholarly societies and a mini-review. Guezguez F; Knaz H; Anane I; Bougrida M; Ben Saad H Expert Rev Respir Med; 2021 Jun; 15(6):823-832. PubMed ID: 33750253 [No Abstract] [Full Text] [Related]
33. FEV(1)/FEV(6) to diagnose airflow obstruction. Comparisons with computed tomography and morbidity indices. Bhatt SP; Kim YI; Wells JM; Bailey WC; Ramsdell JW; Foreman MG; Jensen RL; Stinson DS; Wilson CG; Lynch DA; Make BJ; Dransfield MT Ann Am Thorac Soc; 2014 Mar; 11(3):335-41. PubMed ID: 24450777 [TBL] [Abstract][Full Text] [Related]
34. Lung Function Trajectories Leading to Chronic Obstructive Pulmonary Disease as Predictors of Exacerbations and Mortality. Marott JL; Ingebrigtsen TS; Çolak Y; Vestbo J; Lange P Am J Respir Crit Care Med; 2020 Jul; 202(2):210-218. PubMed ID: 32289231 [No Abstract] [Full Text] [Related]
35. The forgotten message from gold: FVC is a primary clinical outcome measure of bronchodilator reversibility in COPD. Ben Saad H; Préfaut C; Tabka Z; Zbidi A; Hayot M Pulm Pharmacol Ther; 2008 Oct; 21(5):767-73. PubMed ID: 18555715 [TBL] [Abstract][Full Text] [Related]
36. FEV1/FEV6 is effective as a surrogate for FEV1/FVC in the diagnosis of chronic obstructive pulmonary disease. Venkatachalam P; Dwivedi DP; Govindraj V Indian J Tuberc; 2021 Apr; 68(2):230-235. PubMed ID: 33845957 [TBL] [Abstract][Full Text] [Related]
37. Growth differentiation factor-15 is a predictor of important disease outcomes in patients with COPD. Husebø GR; Grønseth R; Lerner L; Gyuris J; Hardie JA; Bakke PS; Eagan TM Eur Respir J; 2017 Mar; 49(3):. PubMed ID: 28298399 [TBL] [Abstract][Full Text] [Related]